Skip to content
What Causes What
MECHANISM− DECREASES

GLP-1 receptor agonist → Major cardiovascular events

Higher GLP-1 receptor agonist decreases Major cardiovascular events.

In 17,604 adults with overweight or obesity, established heart disease, and no diabetes, weekly semaglutide 2.4 mg cut a first heart attack, stroke, or cardiovascular death by 20 percent versus placebo (Lincoff 2023). Liraglutide did the same in type 2 diabetes (Marso 2016). Oral semaglutide was not worse for that same count (Husain 2019).

Randomized trial · Moderate · N=17604

Supported by an experiment or a tightly identified design. Read the caveats.

Mechanism

GLP-1 agonists slow the stomach, raise insulin when glucose is high, and cut appetite. Weight, blood pressure, and lipids then fall. Authors also talk about a direct vessel effect: less inflammation, less plaque strain. The trials count events, not a mechanism assay. Lincoff, Brown-Frandsen, Colhoun and colleagues (2023) assigned 17,604 people aged 45 or older with preexisting cardiovascular disease and a BMI of 27 or more, and no diabetes, to weekly semaglutide 2.4 mg or placebo. Mean follow-up was 39.8 months. The primary composite was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. Events: 569 of 8803 (6.5 percent) on drug versus 701 of 8801 (8.0 percent) on placebo. Hazard ratio 0.80 (95 percent CI 0.72 to 0.90). abstract_only. Marso, Daniels, Brown-Frandsen and colleagues (2016) assigned 9340 people with type 2 diabetes and high cardiovascular risk to daily liraglutide or placebo. Median follow-up was 3.8 years. The same three-point composite occurred in 608 of 4668 (13.0 percent) versus 694 of 4672 (14.9 percent). Hazard ratio 0.87 (0.78 to 0.97). Cardiovascular death 0.78 (0.66 to 0.93). full_text. Husain, Birkenfeld, Donsmark and colleagues (2019) assigned 3,183 people with type 2 diabetes at high cardiovascular risk to daily oral semaglutide or placebo. Median time in the trial was 15.9 months. The trial was built to rule out an 80 percent excess of events, not to prove a cut. Events: 61 of 1591 versus 76 of 1592. Hazard ratio 0.79 (0.57 to 1.11). P less than 0.001 for noninferiority. abstract_only.

Caveats

Someone was assigned a pen, so the stamp is an RCT stamp. SELECT is secondary prevention in people without diabetes. LEADER is type 2 diabetes at high risk. Neither is a primary-prevention claim in lean people. PIONEER 6 is the same three-point count under an oral pen. It was a safety trial. The interval for a reduction crosses 1. Follow-up was short. In SELECT, 16.6 percent left the drug for an adverse event versus 8.2 percent on placebo. Gut symptoms were the usual reason in both injectables. A large share of the event drop tracks weight and the usual risk factors. The authors have not isolated a vessel-only path. Did not hang STEP-HFpEF function, diuretic, NT-proBNP, or NYHA files. Those are symptoms and heart-failure visits, not this three-point count. Did not hang the SELECT HbA1c subgroup, the SELECT death satellite, or the stroke-subtype post-hoc. Did not hang the LEADER design paper, the baseline calcitonin file, the post-myocardial-infarction satellite, or the heart-failure subgroup. This page is a journal entry. It is not medical advice and not a reason to start or stop a drug.

Effect

odds_ratio = 0.8. SELECT HR 0.80 (0.72-0.90) 3-point MACE, N=17604. LEADER HR 0.87 (0.78-0.97), N=9340. PIONEER 6 oral HR 0.79 (0.57-1.11), N=3183, noninferiority.

Nodes

Lifestyle & environmentGLP-1 receptor agonistBiology & endocrinologyMajor cardiovascular events

Named confounders

Cite this page

What Causes What. “GLP-1 receptor agonist → Major cardiovascular events.” https://whatcauseswhat.org/edges/e-glp1-cv (atlas updated 2026-09-02).

https://whatcauseswhat.org/edges/e-glp1-cv

Papers